Interest in regenerative medicine for spine conditions has grown significantly over the past decade. Early enthusiasm led to many unsupported claims, which made it harder for patients to find accurate information. The honest answer a few years ago was that the data was promising but limited. That answer has changed.
A meta-analysis combining the results of nine published studies and nearly 200 patients found that mesenchymal stem cell therapy for degenerative disc disease produced meaningful improvements in both pain and disability. Nearly 90 percent of patients avoided surgery during the follow-up period. Disability scores improved substantially and consistently across the studies, and no significant adverse events were reported.
That does not mean stem cell therapy is right for every patient with back pain. There is still important nuance in how these treatments are selected and delivered. But the evidence has matured enough that this is a real conversation worth having for the right candidates.
What Happens to a Disc That Degenerates
Intervertebral discs are the cushioning structures between the vertebrae of the spine. Each disc has a tough outer ring and a soft inner core. The inner core is mostly water in younger patients, which gives it the ability to absorb pressure and allow movement. As discs age or sustain injury, they lose water content and height, the outer ring can develop tears, and the disc loses its cushioning ability.
This process, called degenerative disc disease, is not actually a single disease. It describes changes that occur over time and can contribute to pain in different ways. Some patients develop axial low back pain from the disc itself. Others develop radicular pain when a degenerated disc presses on a nerve. Some people have significant disc degeneration on imaging with very little pain, while others have only moderate changes and substantial symptoms.
Conventional treatments focus on managing inflammation and pain while the body compensates for the degenerated disc. They do not restore the disc. This is where regenerative approaches are different in concept, though in practice, most current stem cell treatments are likely working through anti-inflammatory and pain-modulating pathways rather than structural disc restoration.
How Mesenchymal Stem Cell Therapy Works
Mesenchymal stem cells are multipotent cells found in bone marrow, adipose tissue, and other sources. They have the ability to modulate inflammation, influence surrounding cells, and in some contexts differentiate into musculoskeletal tissue types. When injected into a degenerated disc, they appear to reduce the inflammatory environment and may help slow the progression of degeneration.
The treatment is typically an outpatient procedure. Cells are harvested from the patient's own bone marrow or fat, processed, and then injected into the affected disc or discs under image guidance. Because the cells come from the patient, the risk of rejection or significant immune reaction is low.
Most of the positive research to date involves intradiscal injection, which is a direct injection into the disc nucleus rather than the epidural space or joint.
What the Research Actually Shows
The meta-analysis referenced above, which synthesized nine studies with 193 patients, found the following:
Disability scores measured by the Oswestry Disability Index improved by an average of 22 points, a clinically significant change
Pain scores improved consistently across studies
89.6 percent of patients in the combined dataset avoided surgery during follow-up
No significant adverse events were reported
These results applied to patients with symptomatic degenerative disc disease who had not responded well to standard conservative care. The follow-up periods extended to six and twelve months across most studies.
The research has not yet reached the scale of large randomized controlled trials, which remain the gold standard. The studies included are mostly smaller series and cohort studies. The consistency of findings across nine separate studies is meaningful, and the safety profile in the current literature is reassuring.
Which Patients Are Worth Discussing This With
Stem cell therapy for disc disease is not a first-line option and is not for every patient with back pain. It is most relevant for patients who:
Have confirmed degenerative disc disease on MRI
Have axial low back pain that is primarily discogenic in origin
Have tried appropriate conservative care, including physical therapy and possibly injections, without lasting relief
Want to explore options that may modify the disc environment rather than only manage symptoms
Are interested in avoiding or delaying surgical intervention
A thorough evaluation, including review of imaging and clinical history, is necessary before recommending this approach.
Frequently Asked Questions About Stem Cell Therapy for Discs
Is stem cell therapy for back pain covered by insurance?
At this time, most commercial and government insurance plans do not cover intradiscal stem cell therapy. It is typically offered on an out-of-pocket basis. Costs vary and we discuss these during the consultation process.
Where do the stem cells come from?
In most protocols used in our practice, cells are harvested from the patient's own bone marrow. This is called an autologous approach, which avoids immune rejection and regulatory concerns associated with donor cell products.
How long before results appear?
Most patients who respond see improvement over two to six months. Results are generally not immediate, which reflects the biological nature of the treatment.
Is this the same as PRP?
No. Platelet-rich plasma is a different treatment using growth factors from the patient's blood. Both are categorized as regenerative medicine, but they are different biologically and clinically.
Talk to Dr. Rubin About Regenerative Options for Your Spine
If you are dealing with chronic back pain from disc degeneration and want to understand whether regenerative options are appropriate for your situation, we can help you review the evidence and your specific case. Dr. Rubin sees patients from throughout Nassau County, Queens, and Long Island at our Garden City and New Hyde Park offices. Call 516-492-3100 or text 516-206-0774 to schedule a consultation.
Written by Dr. Edward Rubin, MD, board-certified in Pain Medicine and Anesthesiology, with fellowship training at Cornell, Columbia, Hospital for Special Surgery, and Memorial Sloan Kettering. Dr. Rubin has been treating chronic pain patients on Long Island for over 20 years.
